Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 164.15 USD 2.31% Market Closed
Market Cap: 10B USD

Wall Street
Price Targets

ASND Price Targets Summary
Ascendis Pharma A/S

Wall Street analysts forecast ASND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ASND is 211.65 USD with a low forecast of 163.62 USD and a high forecast of 303.45 USD.

Lowest
Price Target
163.62 USD
0% Downside
Average
Price Target
211.65 USD
29% Upside
Highest
Price Target
303.45 USD
85% Upside
Ascendis Pharma A/S Competitors:
Price Targets
APGE
Apogee Therapeutics Inc
159% Upside
AUPH
Aurinia Pharmaceuticals Inc
24% Upside
688687
Beijing Kawin Technology Share-holding Co Ltd
75% Upside
NRIX
Nurix Therapeutics Inc
167% Upside
PYC
PYC Therapeutics Ltd
218% Upside
MRUS
Merus NV
105% Upside
MIRM
Mirum Pharmaceuticals Inc
65% Upside
AVTE
Aerovate Therapeutics Inc
11% Downside

Revenue
Forecast

Revenue Estimate
Ascendis Pharma A/S

For the last 8 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 73%. The projected CAGR for the next 3 years is 63%.

73%
Past Growth
63%
Estimated Growth
Estimates Accuracy
5%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Ascendis Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

Net Income Estimate
Ascendis Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-16%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ASND's stock price target?
Price Target
211.65 USD

According to Wall Street analysts, the average 1-year price target for ASND is 211.65 USD with a low forecast of 163.62 USD and a high forecast of 303.45 USD.

What is Ascendis Pharma A/S's Revenue forecast?
Projected CAGR
63%

For the last 8 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 73%. The projected CAGR for the next 3 years is 63%.

Back to Top